Despite the efforts of the scientific and healthcare community, Spain, together with the USA, is the countries with the highest rate of amputation by diabetic foot (OECD, Health at glance, 2017). Therefore, more than ever, we must consider each amputation as a failure of our Healthcare System. It is estimated that 80% of the total amputations done annually are due to arterial occlusive disease (PAD), which causes ischemia in the affected limb. Ischemia in lower limbs represents the most severe state of PAD, and diabetic patients suffer from it in a more advanced and diffuse form than non-diabetic individuals. Current treatment of this pathology is surgical or endovascular revascularization. However, pharmacological and / or surgical treatment has not been shown to be effective. ClinicalTrials.gov reports more than 70 trials (15 of them published) of Cell Therapy for this pathology. Most of them are trials in the initial stages (I-IIa) without reaching Phase III, resulting in an absence of effective treatment in our National Healthcare System for ischemia in the lower limb. Mesenchymal stem cells (MSCs) administration is one of the strategies used to promote the proliferation of collateral vessels in ischemic tissues. Previous clinical trials of the TerCel Network (Red TerCel of the Instituto CarlosIII) and other research groups have shown that it is a Safe and Feasible procedure. However, trials in more advanced stages (phases II-III) with sufficient population and with sufficient follow-up time are necessary to evaluate the efficacy in revascularization and consequently a decrease in the amputation rate. In this project we propose the to introduce a Cellular Medicament administered intramuscularly, allogeneic and cost-effective as therapy in the critical ischemia of lower limbs in diabetic patients without possibility of revascularization or any other therapeutic alternative.
isquemia crítica de miembros inferiores
amputación
diabetes mellitus
célula madre mesenquimal
célula madre mesenquimatosa
terapia avanzada
medicamento celular
medicamento de terapia avanzada
MTA
Acción Estratégica en Salud (AES)
01/01/2019 - 31/12/2022
GARCIA OLMO, DAMIAN
FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
Comunidad de Madrid
Madrid
669,999 €